Georget Oconnor News Today

WASHINGTON — In patients with idiopathic pulmonary fibrosis, yearly lung function decline rates did not improve with two different dosages of ziritaxestat, according to an American Thoracic Society International Conference presentation.“Unfortunately, ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF receiving standard of care,” Toby M.

In retrospective study, 54% mortality rate for those with mucus plugs in 3 or more lung segments

“In addition to potential treatment harms, there are opportunity costs to screening.”